These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


672 related items for PubMed ID: 9916636

  • 21. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
    Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv Fv, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey PJ.
    Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
    [Abstract] [Full Text] [Related]

  • 25. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.
    Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A, Matthews D, Sanders JE, Storb R, Appelbaum FR, Anasetti C.
    Bone Marrow Transplant; 2000 Aug; 26(4):397-404. PubMed ID: 10982286
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia.
    Chiang KY, Van Rhee F, Godder K, Bridges K, Adams S, Mehta J, Henslee-Downey PJ.
    Bone Marrow Transplant; 2001 Mar; 27(5):507-10. PubMed ID: 11313684
    [Abstract] [Full Text] [Related]

  • 28. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 29. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T, Kojima S, Kato K.
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [Abstract] [Full Text] [Related]

  • 30. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA.
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
    Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.
    J Clin Oncol; 2005 Aug 20; 23(24):5788-94. PubMed ID: 16043827
    [Abstract] [Full Text] [Related]

  • 35. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D, Schwaighofer H, Thaler J, Weyrer W, Fink M, Nussbaumer W, Fritsch E, Niederwieser D.
    Wien Klin Wochenschr; 1994 Aug 20; 106(7):201-7. PubMed ID: 8197754
    [Abstract] [Full Text] [Related]

  • 36. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 20; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 37. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    Bertz H, Potthoff K, Finke J.
    J Clin Oncol; 2003 Apr 15; 21(8):1480-4. PubMed ID: 12697870
    [Abstract] [Full Text] [Related]

  • 38. Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO).
    Dini G, Cancedda R, Giorgiani G, Porta F, Messina C, Uderzo C, Pession A, Fagioli F, La Nasa G, Arcese W, Pollichieni S, Zecca M, Lanino E, Mazzolari E, Cesaro S, Balduzzi A, Rondelli R, Vassallo E, Cappelli B, Locatelli F, Association Italiana Ematologia e Oncologia Pediatrica and Gruppo Italiano per il Trapianto Midollo Osseo.
    Haematologica; 2002 Aug 15; 87(8 Suppl):51-7. PubMed ID: 12412391
    [Abstract] [Full Text] [Related]

  • 39. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.
    Bone Marrow Transplant; 2003 Jan 15; 31(2):121-8. PubMed ID: 12621494
    [Abstract] [Full Text] [Related]

  • 40. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.
    Biol Blood Marrow Transplant; 2005 Feb 15; 11(2):122-8. PubMed ID: 15682073
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 34.